BridgeBio has demonstrably advanced its development of a novel therapy for cardiac amyloidosis, leveraging Attruby. Early patient information suggests significant outcomes for patients diagnosed from a debilitating https://attr-cm674167.digiblogbox.com/66527604/firm-improves-cardiac-amyloidosis-treatment-using-attruby